Identification of severe asthma with Type 2 and eosinophilic characteristics refractory to inhaled corticosteroids is now a key part of the clinical assessment, defining those who will respond to monoclonal antibody therapy directed against IgE, IL‐5 and IL‐4/13.1 The gene discussed is IL4; the disease is asthma.